Ashley Mcevoy Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 3 weeks, 4 days ago
Ashley Mcevoy has an estimated net worth of at least $26.9 million*, as of Oct. 28, 2026. They own 52,037 shares of JNJ stock. They have sold 73,323 shares of JNJ stock since 2021, for an estimated $12.9 million.
Ashley Mcevoy $JNJ SEC Form 4 Insider Trading
Ashley Mcevoy has filed a total of 2 insider trades in $JNJ since 2021. Their most recent trade was a sale of 1,400 shares, made on Nov 30, 2022. Their largest trade was a sale of 71,923 shares, made on Nov 30, 2022. We estimate that they now own 52,037 shares of $JNJ, worth an estimated $14.0 million.
Insider Trading at $JNJ
There have been a total of 385 insider trades reported at $JNJ since 2021, with 2,250 shares purchased and 1.5 million shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 13,072 shares reported by Elizabeth Forminard (EVP, Chief Legal Officer), made on Nov 12, 2026.
History of Insider Stock Trades by Ashley Mcevoy
$JNJ Executives and Stock Owners with Insider Trades
-
Peter Fasolo, Exec VP, Chief HR Officer
-
Thibaut Mongon, Exec VP, WW Chair, Consumer
-
William Hait, See Remarks
-
Joseph J Wolk, Exec VP, CFO
-
Joaquin Duato, CEO and Chairman of the Board
-
Timothy Schmid, EVP, WW Chair, MedTech
-
Kathryn E Wengel, EVP, Chief GSC Officer
-
John C Reed, EVP, Innovative Medicine, R&D
-
Elizabeth Forminard, EVP, Chief Legal Officer
-
Robert J Decker, Controller, CAO
-
Robert J Decker, VP Corporate Controller
-
James D. Swanson, EVP, CIO
-
Vanessa Broadhurst, EVP, Global Corp Affairs
-
Jennifer L Taubert, EVP, WWC. Innovative Medicine
-
Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals
-
Kathryn E Wengel, EVP, Chief TO and Risk Officer
-
Ashley Mcevoy, EVP, WW Chair, MedTech
-
James D. Swanson, See Remarks
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.